ResQ Biotech is a spin-off company of the National Hellenic Research Foundation (NHRF), which was founded in 2019 and is based in the Patras Science Park, Greece. The main activity of the company consists in the discovery, preclinical development and commercial exploitation of potentially therapeutic molecules against diseases caused by problematic protein folding, such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. The creation of ResQ Biotech has been based on the high level of expertise developed in the laboratory of Dr. Georgios Skretas at the Institute of Chemical Biology of the NHRF, which concerns the use of biotechnological methods for the discovery of these molecules by applying an innovative synthetic biotechnology methodology. Additionally, the company has extensive experience in the biosynthetic production of difficult proteins, such as human membrane proteins, for further study and characterization. ResQ Biotech's long-standing experience of pre-clinical development and commercial exploitation of scientific research allows for the successful completion of the early stages of the discovery and development of new drugs against these diseases.